Cannabis has been used to treat gastrointestinal (GI) conditions that range from enteric
infections and inflammatory conditions to disorders of motility, emesis and abdominal pain …

There are at least two types of cannabinoid receptor, CB1 and CB2, both G protein coupled.
CB1 receptors are expressed predominantly at nerve terminals and mediate inhibition of …

The effect of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body
weight was assessed in adult, non-obese Wistar rats. The daily administration of SR 141716 …

The enteric nervous system of several species, including the mouse, rat, guinea pig and
humans, contains cannabinoid CB1receptors that depress gastrointestinal motility, mainly by …

We have studied the effect of cannabinoid agonists (CP 55,940 and cannabinol) on
intestinal motility in a model of intestinal inflammation (induced by oral croton oil in mice) …

The endocannabinoids, a family of endogenous lipids that activate cannabinoid receptors,
are released from cells in a stimulus-dependent manner by cleavage of membrane lipid …

The therapeutic actions of cannabinoids have been known for centuries. In the last 25 years
this area of research has grown exponentially with the discovery of specific cannabinoid …

Δ9-Tetrahydrocannabinol (the active ingredient of marijuana), as well as endogenous and
synthetic cannabinoids, exert many biological functions by activating two types of …

Background & Aims: Activation of enteric cannabinoid CB1 receptors inhibits motility in the
small intestine; however, it is not known whether endogenous cannabinoids (anandamide …

We investigated the effect of the cannabinoid agonist (+) WIN552122 on human ileum
longitudinal smooth muscle preparations, either electrically stimulated or contracted by …